HOXB13 and breast cancer: Ma and collaborators have further described the molecular grade index (MGI), a five cell-cycle gene test that, in combination with HOXB13/IL17BR ratio, identifies a subgroup of early ER+BC patients with a very poor clinic outcome, despite endocrine therapy [78].